Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.
Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Today, the American College of Rheumatology, in partnership with the Arthritis Foundation, released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee.
Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.
A new study presented at the 2019 ACR/ARP meeting shows that methotrexate stopped further damage to the hand joints and even perhaps improved bone remodeling in patients with osteoarthritis (OA) of the hand, when they were assessed at 3 and 12 months.
Researchers have found that using the information form ultrasound technology in the treatment protocol did not affect the outcome of the patients with Rheumatoid arthritis. The study titled, “Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial,” was presented at the 2019 ACR/ARP Annual Meeting.
A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis.
A new study found that patients with Down syndrome arthropathy continue to have an approximate year-long delay in diagnosis from the onset of their symptoms, and that optimal therapy for this condition remains unclear.
A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.
A new study finds that children with Down syndrome are at an increased risk of an associated form of arthritis.
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.
Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.
Through a systematic review of published studies going back 50 years, Johns Hopkins Medicine researchers say they have identified a distinct subtype of primary central nervous system lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed.
Today, the American College of Rheumatology, in partnership with the Arthritis Foundation, released two guidelines on juvenile idiopathic arthritis.
Tuberculosis, an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective.
Arthritis is not just an ailment of old age--it can affect children too, causing lifelong pain and disability in its most severe forms. Fortunately, some kids grow out of it. Knowing which patients will develop milder forms of disease could spare them unnecessary treatment and potential medication side effects but currently doctors have no way of predicting disease course or severity.
Fatty acid metabolism is an essential process in tumor growth and proliferation. Despite different attempts to block fatty acid metabolism as a therapeutic strategy to reduce tumor size and growth, the outcome was not always positive.
Squamous cell carcinoma is one of the most common cancers of the skin and mucosa. Treatment options for the advanced stage have been very limited for patients with tumors of the head and neck, i.e. in the mouth, the pharynx or the larynx: If recurrences or metastases occur during or after platinum-based chemotherapy, the disease is generally considered incurable.
When it comes to reducing inflammation to decrease the risk of heart disease and stroke, results from the much-anticipated Cardiovascular Inflammation Reduction Trial indicate that targeting the right inflammatory pathways in at-risk patients is crucial.